" class="no-js "lang="en-US"> Tom Graney - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Tom Graney

Tom Graney

About Tom Graney

Experienced public biotech Chief Executive Officer and Chief Financial Officer. Twenty plus years in leadership roles in General Management, Finance, Strategy and Corporate Development in the biotech/pharma and medical device industries in US, international and global markets for both development stage companies and major commercial stage companies. Independent director of public and private biotech companies Board of Directors.

Related Story

Appointments

 Mogrify Appoints Tom Graney as Non-Executive Director

Mogrify Appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor

November 2 2021

Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in […]